Aortic heart valve company Anteris Technologies (AVR: $23.10) had multiple presentations at the major US conference TCT (Transcatheter Cardiovascular Therapeutics) held in Boston last month. The event has around 11,000 specialists in the field attending and was founded by Dr Martin Leon, who has joined the Anteris Medical Advisory Board earlier this year.

Cogstate's (CGS: $2.09) partner, Eisai Co Ltd, has for the first time in this disease area, delivered unequivocally positive data for its Alzheimer's disease treatment, lecanamab.

Eisai will now seek to file the therapy for full approval with the FDA by the end of March. Eisai will use Cogstate's electronic cognitive test battery to help identify potential patients for treatment, under a US$45 million deal signed in 2020 between the two companies.

Pharmaxis (PXS: $0.084) is using its lysyl oxidase platform to develop a topical application for the removal of scars. Results are due around year's end and may be a driver for this stock over coming months.

ResApp Heath has been acquired by Pfizer at a fully diluted value of $180 million, or $0.208 per share. The company was acquired via a Scheme of Arrangement with an 82% approval based on total shares voted (75% required) and 62% of shareholders voting in favour (50% required). The Scheme was approved by the Supreme Court of NSW last week.

ResApp Diagnostics made a backdoor listing onto the ASX in 2015 through an acquisition by Narhex Life Sciences and being renamed ResApp Health. At the end of December last year the company had accumulated losses of $40.4 million with $3.4 million in cash.

Pharmaxis (PXS: $0.084) is using its lysyl oxidase platform to develop a topical application for the removal of scars. Results are due around year's end and may be a driver for this stock over coming months.

Pharmaxis CEO Gary Phillips said that the company has the first-in-class and best-in-class compounds in this field. According to Phillips at an R&D day earlier this year, the reason why Pharmaxis has extended its R&D programs into scarring is because it's where the science has led the company to.

Imugene (IMU: $0.22) has announced it intends to raise $80 million through a private placement that includes two specialist biotech investment funds with commitments secured. The funds to be raised will support the company's portfolio of immuno-oncology drug development assets. Imugene will have a proforma (June 30) cash balance of $175 million.

Cogstate (CGS: $1.46) has seen its share price oscillate in recent weeks, in sync with the share prices of Eisai Co and Biogen. All three companies will be impacted by the results of the Phase III study with the Alzheimer's disease drug candidate, lecanemab, which is jointly owned by Eisai and Biogen and in clinical development by Eisai. Topline results are due at the end of this month.

Since Boehringer Ingelheim returned the Pharmaxis (PXS: $0.076) drug candidate PXS-4728 in 2020, Pharmaxis has been seeking to find a new indication to trial for the compound, given the level of development work that had been carried out on the compound by Boehringer.

Patrys' (PAB: $0.024) lead drug antibody drug candidate, PAT-DX1, has passed the final manufacturing assessment meeting all of the specification requirements. This allows Patrys to move into final preclinical toxicology testing ahead of the first clinical study planned for the second half of 2023.

Anteris Technologies (AVR: $21.50) presented at the inaugural E&P Healthcare conference this week.

CEO Wayne Paterson believes that the technical risk for the company's novel aortic valve, the DurAVR 3D, has been significantly diminished, down to only 5%-10% following successful implantation into 13 patients. The remaining risk for the company relates primarily to execution.

Anteris is developing a single piece aortic valve that is implanted via catheter, rather than open-chest surgery.